Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

This study has been completed.

Study NCT00000174 Information provided by National Institute on Aging (NIA)

First Received: October 29, 1999 Last Updated: December 8, 2005 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

No publications provided by National Institute on Aging (NIA)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007 Jun;6(6):501-12.